BioCryst Pharmaceuticals,Inc. (NASDAQ:BCRX) Files An 8-K Entry into a Material Definitive Agreement

will receive cash in lieu of fractional shares as part of the Idera Merger Consideration, as specified in the Merger Agreement.

Following the Effective Time, BioCryst common stockholders will own approximately 51.6% of the shares of Holdco Common Stock on a fully diluted basis, and Idera common stockholders will own 48.4%.

Also at the Effective Time, outstanding options to purchase shares of BioCryst Common Stock (the “BioCryst Options”) will accelerate and vest in full and be assumed by Holdco and converted into stock options to purchase shares of Holdco Common Stock (each, a “Holdco Option”) with the same terms and conditions (other than vesting) as applied to the BioCryst Options immediately prior to the Effective Time; however, each such Holdco Option will cover a number of shares of Holdco Common Stock equal to the product of the number of shares of BioCryst Common Stock subject to the BioCryst Option and the BioCryst Exchange Ratio and will have an exercise price per share equal to the amount obtained by dividing the per share exercise price of the BioCryst Option by the BioCryst Exchange Ratio. All BioCryst restricted stock units covering BioCryst Common Stock (“BioCryst RSUs”) will accelerate and vest in full and be converted into restricted stock units covering Holdco Common Stock (“Holdco RSUs”) with the same terms and conditions (other than vesting) as applied to the BioCryst RSUs immediately prior to the Effective Time; however, the Holdco RSUs will cover a number of shares of Holdco Common Stock equal to the product of the number of shares of BioCryst Common Stock subject to the BioCryst RSU and the BioCryst Exchange Ratio.

Also at the Effective Time, outstanding options to purchase shares of Idera Common Stock (the “Idera Options”) and outstanding warrants and pre-funded warrants to purchase shares of Idera Common Stock (“Idera Warrants”) will be assumed by Holdco and, if the Idera Options are held by individuals who are not a party to certain severance and change of control agreements, such options shall accelerate and vest in full. Each Idera Option will be converted into a Holdco Option with the same terms and conditions (other than, in the case described above, vesting) as applied to the option immediately prior to the Effective Time; however, the Holdco Option will cover a number of shares of Holdco Common Stock equal to the product of the number of shares of Idera Common Stock subject to the Idera Option and the Idera Exchange Ratio and will have an exercise price per share equal to the amount obtained by dividing the per share exercise price of the Idera Option by the Idera Exchange Ratio. All Idera Warrants will be converted into a warrant to acquire Holdco Common Stock (“Holdco Warrant”) with the same terms and conditions as applied to the warrant immediately prior to the Effective Time; however, the Holdco Warrant will cover a number of shares of Holdco Common Stock equal to the product of the number of shares of Idera Common Stock subject to the Idera Warrant and the Idera Exchange Ratio and will have an exercise price per share equal to the amount obtained by dividing the per share exercise price of the Idera Option by the Idera Exchange Ratio.

Governance

Under the terms of the Merger Agreement, as of the Effective Time, the corporate headquarters of Holdco and its subsidiaries will be located in Exton, Pennsylvania and the primary research and development facility for Holdco and its subsidiaries will be located in Birmingham, Alabama.

The Merger Agreement provides that, upon the closing of the Mergers, the board of directors of Holdco (the “Holdco Board”) will be comprised of nine members, consisting of (i)four directors designated from the board of directors of BioCryst (the “BioCryst Board”), one of which will be Jon P. Stonehouse, BioCryst’s current chief executive officer, (ii)four directors designated from the board of directors of Idera (the “Idera Board”), one of which will be Vincent J. Milano,Idera’s current chief executive officer, and (iii)one director to be mutually agreed upon by BioCryst’s Board and Idera’s Board. Robert A. Ingram, the current Chairman of the BioCryst Board, will be chairman of the Holdco Board.

The Merger Agreement provides that Vincent J. Milano, the current chief executive officer of Idera, will be Chief Executive Officer of Holdco.

Conditions to the Mergers

The consummation of the Mergers is subject to customary closing conditions, including (i)the adoption of the Merger Agreement by the affirmative vote of the holders of a majority of all outstanding shares of BioCryst Common Stock entitled to vote thereon, (ii)the adoption of the Merger Agreement by the affirmative vote of the holders of a majority of all outstanding shares of Idera capital stock entitled to vote thereon, (iii)the absence of any adverse law or order promulgated, entered, enforced, enacted or issued by any governmental entity that prohibits, restrains or makes illegal the consummation of the Mergers, (iv)the shares of Holdco Common Stock to be issued in the Mergers being approved for listing on the NASDAQ Global Select Market, (v)the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other material government approvals, if required, (vi)the U.S. Securities and Exchange Commission (the “SEC”) having declared effective the FormS-4 Registration Statement of Holdco which will contain the joint proxy statement/prospectus of the parties in connection with the Mergers, (vii)subject to certain materiality exceptions, the accuracy of certain representations and warranties of each of BioCryst and Idera contained in the Merger Agreement and the compliance by each party with the covenants contained in the Merger Agreement, (viii)the receipt of certain opinions from legal counsel regarding the intended tax treatment of the Mergers and (ix)the absence of a material adverse effect with respect to each of BioCryst and Idera. The parties expect the Mergers to be completed in the second quarter of 2018.

Certain Other Terms of the Merger Agreement

The Merger Agreement includes certain representations, warranties and covenants, including, among other things, covenants by BioCryst and Idera to conduct their businesses in the ordinary course during the period between the execution of the Merger Agreement and consummation of the Mergers, to refrain from taking certain actions specified in the Merger Agreement and to use reasonable best efforts to cause the conditions of the Mergers to be satisfied.

Neither BioCryst nor Idera is permitted to solicit, initiate or knowingly encourage or induce, or take any other action designed to facilitate, any competing transaction proposals from third parties or to engage in discussions or negotiations with third parties regarding any competing transaction proposals, subject to certain exceptions. Each party’s board of directors may change its recommendation to its stockholders in response to a superior proposal or an intervening event

if the board of directors determines in good faith that the failure to take such action would constitute a breach of the directors’ fiduciary duties under applicable law.

The Merger Agreement provides for certain termination rights for both BioCryst and Idera. Upon termination of the Merger Agreement under certain specified circumstances,Idera or BioCryst may be required to pay the other party a termination fee of $25,000,000.00. In addition, if the Merger Agreement is terminated by BioCryst or Idera as a result of the other party’s failure to obtain stockholder approval, or is terminated by BioCryst or Idera due to the other party’s breach of its representations and covenants and such breach would result in the closing conditions not being satisfied, then the non-terminating party may be required to pay a fixed expense reimbursement amount of $6,000,000.00.

The foregoing summary does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached hereto as Exhibit2.1 and is incorporated herein by reference.

The Merger Agreement has been attached as an exhibit to this report to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about BioCryst or Idera or to modify or supplement any factual disclosures about BioCryst or Idera in its public reports filed with the SEC. The Merger Agreement includes representations, warranties and covenants of BioCryst and Idera made solely for the purposes of the Merger Agreement and which may be subject to important qualifications and limitations agreed to by BioCryst and Idera in connection with the negotiated terms of the Merger Agreement. Moreover, some of those representations and warranties may not be accurate or complete as of any specified date, may be subject to certain disclosures between the parties and a contractual standard of materiality different from those generally applicable to BioCryst’s or Idera’s SEC filings. In addition, the representations and warranties were made for purposes of allocating risk among the parties to the Merger Agreement and should not be relied upon as establishing factual matters.

Voting Agreement

Simultaneously with the execution of the Merger Agreement, BioCryst entered into a Voting and Support Agreement (the “Voting and Support Agreement”) with 667, L.P. (“”), Baker Brothers Life Sciences, L.P. (“BBLS”) and 14159, L.P., each of which is an affiliate of Baker Bros. Advisors, LP (“Baker Brothers”), and Idera entered into a voting and support agreement with affiliates of Baker Brothers.

Baker Brothers is the beneficial owner of approximately 14% of the currently outstanding BioCryst Common Stock and approximately 9% of the currently outstanding Idera Common Stock. to the Voting and Support Agreement, Baker Brothers has agreed, among other things, to vote its shares in favor of the adoption of the Merger Agreement at the meeting of BioCryst stockholders convened to approve the transaction.

The foregoing summary does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Voting and Support Agreement, which is attached hereto as Exhibit99.1 and is incorporated herein by reference.

Amendment to Registration Rights Agreement

Also in connection with the transactions contemplated by the Merger Agreement, BioCryst, 667 and BBLS executed an amendment (the “Registration Rights Agreement Amendment”) to that certain Registration Rights Agreement (the “Registration Rights Agreement”), dated as of March15, 2017, by and among BioCryst, 667 and BBLS. The Registration Rights Agreement Amendment provides for the continuation of the registration rights provided to the Registration Rights Agreement in the event of a recapitalization, merger, consolidation, reorganization or other similar transaction (which will include the BioCryst Merger).

The foregoing summary does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Registration Rights Agreement Amendment, which is attached hereto as Exhibit10.1 and is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On January21, 2018, the BioCryst Board determined that it was in the best interests of BioCryst and its stockholders to amend the Amended and RestatedBy-Lawsof BioCryst (the “Bylaws”) and by resolution authorized, approved and adopted an amendment to theBylaws(the “BylawsAmendment”). TheBylawsAmendment became effective immediately upon its adoption. TheBylawsAmendment designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for (i)any derivative action or proceeding brought on behalf of the BioCryst, (ii)any action asserting a claim of breach of a fiduciary duty owed by any director, officer, stockholder, employee or agent of BioCryst to the BioCryst or its stockholders, (iii)any action asserting a claim against BioCryst or any director, officer, stockholder, employee or agent of BioCryst arising out of or relating to any provision of the General Corporation Law of Delaware or BioCryst’s Certificate of Incorporation or the By-Laws, or (iv)any action asserting a claim against BioCryst or any director, officer, stockholder, employee or agent of BioCryst governed by the internal affairs doctrine of the State of Delaware. The Bylaws Amendment further provides that, in the event that the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding,the sole and exclusive forum for such action or proceeding shall be another state or federal court located within the State of Delaware, in each such case, unless the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) has dismissed a prior action by the same plaintiff asserting the same claims because such court lacked personal jurisdiction over an indispensable party named as a defendant therein.

The foregoing description of theBylawsAmendment does not purport to be a complete description and is qualified in its entirety by reference to the full text of theBylawsAmendment, which is attached hereto as Exhibit3.1 and is incorporated herein by reference.

Additional Information and Where to Find It

In connection with the proposed Mergers, BioCryst and Idera plan to file with the SEC and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus regarding the proposed transaction. BEFORE MAKING ANY VOTING DECISION, BIOCRYST’S AND IDERA’S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY WHEN IT BECOMES

AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF BIOCRYST AND IDERA WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and stockholders will be able to obtain a free copy of the joint proxy statement/prospectus and other documents containing important information about BioCryst and Idera, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. BioCryst and Idera make available free of charge at www.biocryst.com and www.iderapharma.com, respectively (in the “Investors” section), copies of materials they file with, or furnish to, the SEC.

Participants in the Solicitation

This document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. BioCryst,Idera and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of BioCryst and Idera in connection with the proposed Mergers. Security holders may obtain information regarding the names, affiliations and interests of BioCryst’s directors and officers in BioCryst’s Annual Report on Form10-K for the fiscal year ended December31, 2016, which was filed with the SEC on February27, 2017, and its definitive proxy statement for the 2017 annual meeting of stockholders, which was filed with the SEC on April12, 2017. Security holders may obtain information regarding the names, affiliations and interests of Idera’s directors and officers in Idera’s Annual Report on Form10-K for the fiscal year ended December31, 2016, which was filed with the SEC on March15, 2017, and its definitive proxy statement for the 2017 annual meeting of stockholders, which was filed with the SEC on April28, 2017. To the extent the holdings of BioCryst securities by BioCryst’s directors and executive officers or the holdings of Idera securities by Idera’s directors and executive officers have changed since the amounts set forth in BioCryst’s or Idera’s respective proxy statement for its 2017 annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed Mergers will be included in the joint proxy statement/prospectus relating to the proposed Mergers when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, BioCryst’s website at www.biocryst.com and Idera’s website at www.iderapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,” “contemplate,” “estimate,” “predict,” “potential” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the expected timing of the closing of the Mergers; the ability of the parties to complete the Mergers considering the various closing conditions; the expected benefits of the Mergers, such as efficiencies, cost savings, tax benefits, enhanced revenues and cash flow,

growth potential, market profile and financial strength; the competitive ability and position of the combined company; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from BioCryst’s and Idera’s plans, estimates or expectations could include, but are not limited to: (i)BioCryst or Idera may be unable to obtain stockholder approval as required for the Mergers; (ii)conditions to the closing of the Mergers may not be satisfied; (iii)the Mergers may involve unexpected costs, liabilities or delays; (iv)the effect of the announcement of the Mergers on the ability of BioCryst or Idera to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom BioCryst or Idera does business, or on BioCryst’s or Idera’s operating results and business generally; (v)BioCryst’s or Idera’s respective businesses may suffer as a result of uncertainty surrounding the Mergers and disruption of management’s attention due to the Mergers; (vi)the outcome of any legal proceedings related to the Mergers; (vii)BioCryst or Idera may be adversely affected by other economic, business, and/or competitive factors; (viii)the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; (ix)risks that the Mergers disrupts current plans and operations and the potential difficulties in employee retention as a result of the Mergers; (x)the risk that BioCryst or Idera may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xi)risks that the anticipated benefits of the Mergers or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii)the impact of legislative, regulatory, competitive and technological changes; (xiii)risks relating to the value of the new holding company shares to be issued in the Mergers; (xiv)expectations for future clinical trials, the timing and potential outcomes of clinical studies and interactions with regulatory authorities; and (xv)other risks to the consummation of the Mergers, including the risk that the Mergers will not be consummated within the expected time period or at all. Additional factors that may affect the future results of BioCryst and Idera are set forth in their respective filings with the SEC, including each of BioCryst’s and Idera’s most recently filed Annual Report on Form10-K, subsequent Quarterly Reports on Form10-Q, Current Reports on Form8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of BioCryst’s Quarterly Report on Form10-Q for the quarter ended September30, 2017 under the heading “Risk Factors” and Item 1A of Idera’s Annual Report on Form10-K for the fiscal year ended December31, 2016 under the heading “Risk Factors.” The risks and uncertainties described above and in BioCryst’s most recent Quarterly Report on Form10-Q and Idera’s most recent Annual Report on Form10-K are not exclusive and further information concerning BioCryst and Idera and their respective businesses, including factors that potentially could materially affect their respective businesses, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that BioCryst and Idera file from time to time with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by law, BioCryst and Idera assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

* The schedules to the Agreement and Plan of Merger have been omitted from this filing to Item 601(b)(2)of Regulation S-K. Registrant will furnish copies of such schedules to the Securities and Exchange Commission upon request by the Commission.

BIOCRYST PHARMACEUTICALS INC ExhibitEX-2.1 2 a18-3548_1ex2d1.htm EX-2.1 EXHIBIT 2.1   AGREEMENT AND PLAN OF MERGER   among   BIOCRYST PHARMACEUTICALS,…To view the full exhibit click here
About BioCryst Pharmaceuticals,Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.